Compare Gilead Sciences, Inc. (GILD) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Boston Beer Company Inc — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.40B), while Boston Beer Company Inc trades at $171.2 (market cap $1.76B). The key difference: Gilead Sciences, Inc. is far larger — about 103.6× Boston Beer Company Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Boston Beer Company Inc for 59 Days on average.
| GILD | SAM | |
|---|---|---|
Market Cap | $182.40B | $1.76B |
Volume | 4,469,821 | 264,496 |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $260.05 |
52-Week Low | $116.74 | $161.08 |
Typical Hold Time | 111 Days | 59 Days |
Enterprise Value | $205.46B | $1.53B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
SAM trades at $168.16, down 1.3% over the past day, with a neutral technical signal and bearish moving averages. The stock has a P/E of 22.66 and P/S of 0.94, indicating moderate valuation. Recent earnings missed expectations in Q1 and Q2 2026, but net income improved to $108.47M in 2025. The company is expanding its product portfolio with new cocktails and coolers, though volume growth remains a challenge.
The outlook is mixed: analyst consensus is a $204.44 price target with a majority hold rating, but negative net income margin and ROE highlight profitability risks. Key opportunities include brand investments and innovation, while risks involve declining volumes and cost pressures in a competitive market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
